In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Even as it's become clear that an inherited susceptibility to some cancers is more common than once thought, genetic testing of family members of cancer patients hasn't increased as much as experts had hoped.